BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
Status:
Completed
Trial end date:
2020-04-10
Target enrollment:
Participant gender:
Summary
New treatments are greatly needed for patients with recurrent glioblastoma. Metronomic
temozolomide is a standard treatment option but has, at best, modest activity. The
nanoliposomal irinotecan may be much more active than the parent compound irinotecan since
nanoliposomal irinotecan's ability to cross the blood brain barrier is improved. This phase I
study will establish the MTD of the combination of nanoliposomal irinotecan in combination
with temozolomide safety and preliminary clinical efficacy of the combination of
nanoliposomal irinotecan and metronomic temozolomide.